Avid Bioservices, Inc. to Present at IBC'S Antibody Engineering & Therapeutics Conference December 5-9, 2010
Published: Nov 29, 2010
TUSTIN, CA and SAN DIEGO, CA--(Marketwire - November 29, 2010) - Avid Bioservices, Inc., a leading provider of integrated commercial and clinical manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc., announced that company representatives will present a poster at IBC's Antibody Engineering & Therapeutics Conference in San Diego, CA. With a cGMP manufacturing facility in Orange County, CA, Avid will highlight its experience developing and implementing a comprehensive comparability program to increase the manufacturing yield to support larger Phase IIb clinical trials for Peregrine's lead monoclonal antibody bavituximab.
"Designing and implementing a robust comparability program was critical to advance Peregrine's bavituximab into larger Phase IIb clinical trials," said Richard Richieri, senior director, technical services, of Avid Bioservices. "We developed an integrated regulatory and manufacturing strategy to implement a second-generation process to increase yield and clinical supply of bavituximab. With input from regulatory, process sciences, and quality functions, we ensured a successful implementation of significant process changes to support larger clinical trials."
Avid's poster is titled "Demonstrating Comparability of a Phase II Monoclonal Antibody Product in Clinical Trials Resulting from Changes in Cell Line and Manufacturing Processes" and will be on display in the exhibit hall December 6-8, 2010 at the Hilton San Diego Bayfront Hotel. Avid is also hosting an exhibit at the conference, booth #204.
For additional information on IBC's Antibody Engineering & Therapeutics Conference, please visit http://www.ibclifesciences.com/antibodyeng/overview.xml.
About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cell banking, stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.